FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043067498> ?p ?o ?g. }

• W2043067498 endingPage "1173" @default.
• W2043067498 startingPage "1167" @default.
• W2043067498 abstract "We conducted a non-randomised controlled phase II trial to investigate the role of preoperative administration of interleukin-2 (IL-2) in patients with renal cell carcinoma undergoing tumour nephrectomy. A total of 120 consecutive patients were allocated alternately to the two study groups: perioperative immunomodulation with IL-2 (IL-2 group; n=60) and perioperative immunomonitoring without immunomodulation (control group; n=60). Patients from the IL-2 group received four doses of 10 x 10(6) IU m(-2) twice daily subcutaneously a week before operation followed by a daily maintenance dose of 3 x 10(6) IU m(-2) subcutaneously until a day before the operation. Parameters of cellular and humoral immunity (leucocytes, T-cell markers CD3, CD4, and CD8, B-cell marker CD19, monocyte marker CD14, natural killer (NK) cell markers CD16, CD56, and CD57, activation markers CD6, CD25, CD28, and CD69, progenitor cell marker CD34, as well as IL-2, IL-6, IL-10, soluble IL-2 receptor, IL-1 receptor antagonist, transforming growth factor-beta1, and vascular endothelial growth factor) were measured in peripheral venous blood at various intervals. Interleukin-2-related toxicity was WHO grade 1 (24%), 2 (67%), and 3 (9%). In the postoperative period, T-cell markers, activation markers, and NK cell markers decreased, and IL-6 and IL-10 increased. However, all these alterations were significantly less accentuated in patients who had been pretreated with IL-2. Median follow-up was 40 months. Tumour-specific survival in the IL-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04). A similar effect was found for progression-free survival. We conclude that IL-2 can be safely administered in the perioperative period and modulates immunological parameters. However, to validate the survival data, a larger randomised phase III trial is needed." @default.
• W2043067498 created "2016-06-24" @default.
• W2043067498 creator A5023716783 @default.
• W2043067498 creator A5037663259 @default.
• W2043067498 creator A5068351103 @default.
• W2043067498 creator A5069059653 @default.
• W2043067498 creator A5072285845 @default.
• W2043067498 creator A5091028938 @default.
• W2043067498 date "2006-10-10" @default.
• W2043067498 modified "2023-10-16" @default.
• W2043067498 title "Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial" @default.
• W2043067498 cites W1755178355 @default.
• W2043067498 cites W1917111603 @default.
• W2043067498 cites W1963592300 @default.
• W2043067498 cites W1967836453 @default.
• W2043067498 cites W1987171792 @default.
• W2043067498 cites W1990113106 @default.
• W2043067498 cites W2008929652 @default.
• W2043067498 cites W2021256410 @default.
• W2043067498 cites W2021974371 @default.
• W2043067498 cites W2034932355 @default.
• W2043067498 cites W2043717646 @default.
• W2043067498 cites W2045908268 @default.
• W2043067498 cites W2047301850 @default.
• W2043067498 cites W2053833244 @default.
• W2043067498 cites W2055384719 @default.
• W2043067498 cites W2075222049 @default.
• W2043067498 cites W2079767086 @default.
• W2043067498 cites W2083040816 @default.
• W2043067498 cites W2083887116 @default.
• W2043067498 cites W2084333330 @default.
• W2043067498 cites W2085196145 @default.
• W2043067498 cites W2097056943 @default.
• W2043067498 cites W2112113822 @default.
• W2043067498 cites W2116661424 @default.
• W2043067498 cites W2116812203 @default.
• W2043067498 cites W2133157945 @default.
• W2043067498 cites W2143813821 @default.
• W2043067498 cites W2144390074 @default.
• W2043067498 cites W2417551700 @default.
• W2043067498 doi "https://doi.org/10.1038/sj.bjc.6603391" @default.
• W2043067498 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2360567" @default.
• W2043067498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17031403" @default.
• W2043067498 hasPublicationYear "2006" @default.
• W2043067498 type Work @default.
• W2043067498 sameAs 2043067498 @default.
• W2043067498 citedByCount "39" @default.
• W2043067498 countsByYear W20430674982012 @default.
• W2043067498 countsByYear W20430674982013 @default.
• W2043067498 countsByYear W20430674982014 @default.
• W2043067498 countsByYear W20430674982016 @default.
• W2043067498 countsByYear W20430674982017 @default.
• W2043067498 countsByYear W20430674982018 @default.
• W2043067498 countsByYear W20430674982019 @default.
• W2043067498 countsByYear W20430674982020 @default.
• W2043067498 countsByYear W20430674982022 @default.
• W2043067498 countsByYear W20430674982023 @default.
• W2043067498 crossrefType "journal-article" @default.
• W2043067498 hasAuthorship W2043067498A5023716783 @default.
• W2043067498 hasAuthorship W2043067498A5037663259 @default.
• W2043067498 hasAuthorship W2043067498A5068351103 @default.
• W2043067498 hasAuthorship W2043067498A5069059653 @default.
• W2043067498 hasAuthorship W2043067498A5072285845 @default.
• W2043067498 hasAuthorship W2043067498A5091028938 @default.
• W2043067498 hasBestOaLocation W20430674981 @default.
• W2043067498 hasConcept C126322002 @default.
• W2043067498 hasConcept C167672396 @default.
• W2043067498 hasConcept C170493617 @default.
• W2043067498 hasConcept C203014093 @default.
• W2043067498 hasConcept C2776090121 @default.
• W2043067498 hasConcept C2777371288 @default.
• W2043067498 hasConcept C2777472916 @default.
• W2043067498 hasConcept C2908885563 @default.
• W2043067498 hasConcept C71924100 @default.
• W2043067498 hasConcept C79484868 @default.
• W2043067498 hasConcept C8891405 @default.
• W2043067498 hasConcept C90924648 @default.
• W2043067498 hasConceptScore W2043067498C126322002 @default.
• W2043067498 hasConceptScore W2043067498C167672396 @default.
• W2043067498 hasConceptScore W2043067498C170493617 @default.
• W2043067498 hasConceptScore W2043067498C203014093 @default.
• W2043067498 hasConceptScore W2043067498C2776090121 @default.
• W2043067498 hasConceptScore W2043067498C2777371288 @default.
• W2043067498 hasConceptScore W2043067498C2777472916 @default.
• W2043067498 hasConceptScore W2043067498C2908885563 @default.
• W2043067498 hasConceptScore W2043067498C71924100 @default.
• W2043067498 hasConceptScore W2043067498C79484868 @default.
• W2043067498 hasConceptScore W2043067498C8891405 @default.
• W2043067498 hasConceptScore W2043067498C90924648 @default.
• W2043067498 hasIssue "9" @default.
• W2043067498 hasLocation W20430674981 @default.
• W2043067498 hasLocation W20430674982 @default.
• W2043067498 hasLocation W20430674983 @default.
• W2043067498 hasLocation W20430674984 @default.
• W2043067498 hasOpenAccess W2043067498 @default.
• W2043067498 hasPrimaryLocation W20430674981 @default.
• W2043067498 hasRelatedWork W1584600549 @default.
• W2043067498 hasRelatedWork W1982872285 @default.

• next